SCHEMBL20127182

SCHEMBL20127182

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc(C4(c5ccccc5)c5ccccc5-c5ccc6c(ccc7ccccc76)c54)cc3)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 4/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPK1 P28482 3/20 0.37
ATM Q13315 2/20 0.37
TP53 P04637 2/20 0.37
HSD17B10 Q99714 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TSHR P16473 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 4/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
OPRK1 P41145 1/20 0.37
NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20127169 0.94 MAPT (0.40) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL20127175 0.93 MAPT (0.38) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL20127183 0.93 MAPT (0.38) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22868719 0.91 MAPT (0.34) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL24307120 0.90 MAPT (0.42) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22868875 0.90 MEN1 (0.37) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22869076 0.89 MEN1 (0.36) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22868947 0.89 MEN1 (0.38) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22868717 0.88 MAPT (0.34) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22868715 0.88 CYP11B1 (0.33) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2020-08-18 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, CRY2, PER2 MAPT 1073/4885SMN1; SMN2 4089/4885ALDH1A1 526/4885
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CRY2, PER2 MAPT 1073/4885SMN1; SMN2 4089/4885ALDH1A1 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.